20/20 Biolabs, Inc.
AIDX · Services-Testing Laboratories · 10.6M shares · EDGAR filings ↗
Grade
D50gen composite 27pct→55; negative equity (distress)
Notable findings
- Negative equityNegative book equity (debt/equity -3.88)
- Weak liquidityCurrent ratio 0.60 (<1)
- Notable holderHeld by 1 notable fund(s): CITADEL ADVISORS LLC (as of 2026-03-31)
- Revenue declineRevenue -36.2% YoY
Quarterly revenue
Last 2 quarters · from SEC filings.
Key metrics
Return on equity
19447.7%
Return on assets
-90.4%
ROIC
-4751.0%
Revenue growth (QoQ)
-36.2%
Debt / equity
-3.9×
Current ratio
0.6×
EBITDA
-$3M
Tangible book value
-$221K
Cash & investments
$1M
Leadership & compensation
| Name | Role | Latest total comp |
|---|---|---|
| Jonathan Cohen | Chief Executive Officer | $325K FY2025 |
| Bergman Alan B. | Chief Financial Officer | — |
| Jiming Zhou | Chief Operating Officer | $226K FY2025 |
| Michael Lebowitz | Officer | $152K FY2025 |
| COHEN RICHARD M | Director | — |
| Compton John G. | Director | — |
| Rollins John Woodson | Director | — |
| Ross Michael A. | Director | — |
Officers & directors from SEC filings (Form 4 + DEF 14A proxy); compensation is the latest reported fiscal year.
Insider transactions · last 6 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-02-19 | Rollins John Woodson | Conversion | 13K | — |
| 2026-02-19 | Rollins John Woodson | Conversion | 6.1K | — |
| 2026-02-19 | Ross Michael A. | Conversion | 31 | — |
| 2026-02-19 | Compton John G. | Conversion | 7.7K | — |
| 2026-02-19 | COHEN RICHARD M | Conversion | 7.7K | — |
All non-derivative Form 4 activity (SEC), newest first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-07-01 | 2026-07-01 | 0001213900-26-074182 ↗ |
| DEF 14A | 2026-06-23 | 2026-08-18 | 0001213900-26-071172 ↗ |
| 8-K | 2026-05-26 | 2026-05-19 | 0001213900-26-061039 ↗ |
| 10-Q | 2026-05-20 | 2026-03-31 | 0001213900-26-059542 ↗ |
| 8-K | 2026-05-20 | 2026-05-20 | 0001213900-26-059526 ↗ |
| 8-K | 2026-04-28 | 2026-04-23 | 0001213900-26-048257 ↗ |
| 8-K | 2026-04-01 | 2026-03-31 | 0001213900-26-037770 ↗ |
| 10-K | 2026-03-31 | 2025-12-31 | 0001213900-26-037667 ↗ |